文献速递真菌感染

接受布鲁顿酪氨酸激酶抑制剂治疗患者的真菌感染——从流行病学到临床结局:一项系统综述

Fungal infection in patients treated with Bruton tyrosine kinase inhibitor-from epidemiology to clinical outcome: a systematic review.
PubMed 文献 · Clin Microbiol Infect · 2024-12-30

该系统综述纳入92项临床试验/队列研究和115篇病例报告/病例系列,分析接受布鲁顿酪氨酸激酶抑制剂(BTKi)治疗患者的侵袭性真菌感染(IFI)。临床试验/队列中报告736例IFI,以念珠菌病、曲霉病和耶氏肺孢子菌肺炎为主;病例报告中以曲霉病最常见。感染期间停用BTKi可提高生存率。

要点

  • 临床试验/队列中IFI以念珠菌病(31.8%)、曲霉病(30.8%)和耶氏肺孢子菌肺炎(16.8%)为主。
  • 病例报告中主要IFI为曲霉病(50.7%)、隐球菌病(15.6%)、耶氏肺孢子菌肺炎(12.3%)和毛霉病(10.9%)。
  • 感染期间停用BTKi时生存率提高。

核心结论

  • 淋巴细胞恶性肿瘤的靶向治疗带来了感染并发症的新问题。
  • 监测接受第二、三代BTKi治疗患者的IFI对改善这些表现的管理至关重要。

研究设计与样本

  • 系统综述,检索PubMed、Embase和Web of Science数据库,按PRISMA指南报告。
  • 纳入病例报告、病例系列、临床试验和队列研究。
  • 纳入92项回顾性和前瞻性临床试验/队列研究共25215例患者,以及115篇病例报告/病例系列共211例患者。
  • 因临床试验/队列研究异质性显著,仅进行流行病学分析,未做正式发病率分析;流行病学数据以描述性统计呈现。

主要发现

  • 临床试验/队列中报告736例IFI,包括念珠菌病234例(31.8%)、曲霉病227例(30.8%)和耶氏肺孢子菌肺炎124例(16.8%)。
  • 病例报告/病例系列中,155例(73.5%)为慢性淋巴细胞白血病,56例(26.5%)为其他恶性肿瘤。
  • 病例报告/病例系列中主要IFI为曲霉病107例(50.7%)、隐球菌病33例(15.6%)、耶氏肺孢子菌肺炎26例(12.3%)和毛霉病23例(10.9%)。
  • 从启动BTKi至发生IFI的中位延迟时间:曲霉病2.3、隐球菌病4.0、耶氏肺孢子菌肺炎3.0、毛霉病3.0。
  • 感染期间停用BTKi时生存率提高。

临床怎么用

  • 监测接受第二、三代BTKi治疗患者的IFI对改善这些表现的管理至关重要。

局限性

  • 临床试验/队列研究异质性显著,仅进行流行病学分析,未做正式发病率分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Bruton tyrosine kinase inhibitor (BTKi) has emerged as a key treatment for B-cell lymphomas. Despite its efficacy in the treatment of malignancies, numerous cases of invasive fungal infections (IFI) have been reported in patients receiving ibrutinib, a first-generation BTKi. Cases of invasive aspergillosis have also been reported with acalabrutinib and zanubrutinib. OBJECTIVES: The objective of this study was to provide an overview of the pathogens involved, the time of onset of infections and factors influencing survival. METHODS: Data sources: PubMed, Embase and Web of Science databases were used, and the results were reported according to Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. STUDY ELIGIBILITY CRITERIA: Case reports, case series, clinical trials and cohort studies were included. PARTICIPANTS: All reported cases of IFI in patients treated with BTKi were analysed. For case reports/case series, demographic, microbiological and outcome data were retrieved. Assessment of risk of bias: Given the significant heterogeneity in clinical trials/cohort studies, only epidemiological analysis was performed, without formal incidence analysis. Methods of data synthesis: Epidemiologic data were presented as descriptive statistics. RESULTS: In total, 25 215 patients from 92 retrospective and prospective clinical trials/cohort studies and 211 patients from 115 case reports/case series were included. Among clinical trials/cohorts, 736 IFI were reported, including 234 candidiasis (31.8%), 227 aspergillosis (30.8%) and 124 Pneumocystis jirovecii pneumonia (PJP) (16.8%). Among the case reports/case series, 155 (73.5%) had chronic lymphocytic leukaemia, and 56 (26.5%) had other malignancies. The main IFI were aspergillosis (n = 107, 50.7%), cryptococcosis (n = 33, 15.6%), PJP (n = 26, 12.3%) and mucormycosis (n = 23, 10.9%). The median delay between the initiation of BTKi and IFI was 2.3, 4.0, 3.0 and 3.0 for aspergillosis, cryptococcosis, PJP and mucormycosis, respectively. The survival rate improved when BTKi was discontinued during infection. CONCLUSIONS: Targeted therapies in lymphocytic malignancies raised new issues concerning infectious complications. Monitoring IFI in patients receiving second- and third-generation BTKi is crucial for improving the management of these manifestations.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Gibert C, Blaize M, Fekkar A, et al. Fungal infection in patients treated with Bruton tyrosine kinase inhibitor-from epidemiology to clinical outcome: a systematic review. Clin Microbiol Infect. 2024. PMID: 39742965. doi:10.1016/j.cmi.2024.12.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。